Celldex Therapeutics (DB:TCE2) - Prezzo delle azioni, notizie e analisi

TCE2 Panoramica delle azioni

Celldex Therapeutics, Inc. è una società biofarmaceutica che si occupa dello sviluppo di anticorpi terapeutici monoclonali e bispecifici per il trattamento di varie malattie. Maggiori dettagli

TCE2 analisi fondamentale
Punteggio fiocco di neve
Valutazione	1/6
Crescita futura	2/6
Prestazioni passate	0/6
Salute finanziaria	6/6
Dividendi	0/6

Premi

Si prevede che i ricavi cresceranno 74.83% all'anno

Analisi del rischio

Attualmente non redditizio e non si prevede che diventerà redditizio nei prossimi 3 anni

Gli azionisti sono stati diluiti nell'ultimo anno

Prezzo delle azioni volatile negli ultimi 3 mesi

Celldex Therapeutics, Inc. Concorrenti

Biotest

XTRA:BIO3

€1.4b

Formycon

XTRA:FYB

€827.2m

Heidelberg Pharma

XTRA:HPHA

€103.9m

2invest

XTRA:2INV

€63.8m

Storia dei prezzi e prestazioni

Riepilogo dei massimi storici, delle variazioni e dei cali di prezzo di tutti i tempi per Celldex Therapeutics
Prezzi storici delle azioni
Prezzo attuale dell'azione	US$24.80
Massimo di 52 settimane	US$47.80
Minimo di 52 settimane	US$21.80
Beta	1.59
1Variazione di 1 mese	-6.77%
Variazione a 3 mesi	-21.52%
Variazione di 1 anno	-1.59%
3Variazione a 3 anni	-30.57%
Variazione a 5 anni	1,080.95%
Variazione dall'IPO	-55.07%

Notizie e aggiornamenti recenti

Recent updates

Rendimenti per gli azionisti

	TCE2	DE Biotechs	DE Mercato
7D	2.5%	-0.7%	-0.02%
1Y	-1.6%	-17.2%	8.2%

Ritorno vs Industria: TCE2 ha superato il German Biotechs che ha restituito -17.2 % nell'ultimo anno.

Rendimento vs Mercato: TCE2 ha avuto una performance inferiore al mercato German che ha registrato un rendimento 8.2 % nell'ultimo anno.

Volatilità dei prezzi

Is TCE2's price volatile compared to industry and market?
TCE2 volatility
TCE2 Average Weekly Movement	8.3%
Biotechs Industry Average Movement	6.4%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	10.9%
10% least volatile stocks in DE Market	2.4%

Prezzo delle azioni stabile: Il prezzo delle azioni di TCE2 è stato volatile negli ultimi 3 mesi.

Volatilità nel tempo: La volatilità settimanale ( 8% ) di TCE2 è rimasta stabile nell'ultimo anno, ma è comunque superiore al 75% delle azioni German.

Informazioni sull'azienda

Fondato	I dipendenti	AMMINISTRATORE DELEGATO	Sito web
1983	160	Anthony Marucci	www.celldex.com

Celldex Therapeutics, Inc. è una società biofarmaceutica impegnata nello sviluppo di anticorpi terapeutici monoclonali e bispecifici per il trattamento di varie malattie. I suoi candidati farmaci includono terapie a base di anticorpi per il trattamento di pazienti affetti da malattie infiammatorie, allergiche, autoimmuni e altre patologie devastanti. L'azienda ha in programma lo sviluppo clinico di CDX-0159, un anticorpo monoclonale di Fase II che lega il recettore tirosin-chinasi KIT e ne inibisce l'attività.

Celldex Therapeutics, Inc. Riepilogo dei fondamenti

Come si confrontano gli utili e i ricavi di Celldex Therapeutics con la sua capitalizzazione di mercato?
TCE2 statistiche fondamentali
Capitalizzazione di mercato	€1.67b
Guadagni(TTM)	-€147.96m
Ricavi(TTM)	€9.58m

179.7x

Rapporto P/S

-11.6x

Rapporto P/E

TCE2 è sopravvalutato?

Vedi Fair Value e analisi di valutazione

Guadagni e ricavi

Statistiche chiave sulla redditività dall'ultima relazione sugli utili (TTM)
TCE2 Conto economico (TTM)
Ricavi	US$9.98m
Costo del fatturato	US$147.04m
Profitto lordo	-US$137.06m
Altre spese	US$17.02m
Guadagni	-US$154.08m

Ultimi guadagni dichiarati

Sep 30, 2024

Prossima data di guadagno

n/a

Utile per azione (EPS)	-2.32
Margine lordo	-1,373.91%
Margine di profitto netto	-1,544.48%
Rapporto debito/patrimonio netto	0%

Come si è comportato TCE2 nel lungo periodo?

Vedi performance storica e confronto

TCE2 Panoramica delle azioni

Premi

Analisi del rischio

Celldex Therapeutics, Inc. Concorrenti

XTRA:BIO3

€1.4b

XTRA:FYB

€827.2m

XTRA:HPHA

€103.9m

XTRA:2INV

€63.8m

Storia dei prezzi e prestazioni

Notizie e aggiornamenti recenti

Celldex Therapeutics, Inc. Announces First Patient Dosed in Phase 1 Healthy Volunteer Study of CDX-622, a Bispecific Antibody, for the Treatment of Inflammatory Diseases

Founder recently bought €290k worth of stock

Third quarter 2024 earnings released: US$0.64 loss per share (vs US$0.81 loss in 3Q 2023)

Celldex Therapeutics, Inc. Announces Positive Results from its Phase 2 Clinical Trial of Barzolvolimab

New major risk - Revenue and earnings growth

New major risk - Revenue and earnings growth

Recent updates

Celldex Therapeutics, Inc. Announces First Patient Dosed in Phase 1 Healthy Volunteer Study of CDX-622, a Bispecific Antibody, for the Treatment of Inflammatory Diseases

Founder recently bought €290k worth of stock

Third quarter 2024 earnings released: US$0.64 loss per share (vs US$0.81 loss in 3Q 2023)

Celldex Therapeutics, Inc. Announces Positive Results from its Phase 2 Clinical Trial of Barzolvolimab

New major risk - Revenue and earnings growth

New major risk - Revenue and earnings growth

Second quarter 2024 earnings released: US$0.54 loss per share (vs US$0.65 loss in 2Q 2023)

Celldex Therapeutics, Inc. Presents Positive Topline Results from Barzolvolimab Phase 2 Study in Chronic Inducible Urticaria

New minor risk - Share price stability

Celldex Therapeutics Initiates Global Phase 3 Program for Barzolvolimab in Patients with Chronic Spontaneous Urticaria

Senior VP & Chief Medical Officer recently sold €1.5m worth of stock

Celldex Therapeutics Presents Data Demonstrating Profound Improvements in Angioedema in Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria At Eaaci 2024

Senior VP recently sold €314k worth of stock

Celldex Therapeutics, Inc. Announces First Patient Dosed in Phase 2 Study of Barzolvolimab in Prurigo Nodularis

First quarter 2024 earnings released: US$0.56 loss per share (vs US$0.62 loss in 1Q 2023)

Celldex Therapeutics, Inc., Annual General Meeting, Jun 13, 2024

Celldex Therapeutics, Inc. Announces Completion of Enrollment in Phase 2 Study of Barzolvolimab in Patients with Chronic Inducible Urticaria

Celldex Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $400.44 million.

Celldex Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $400.44 million.

Celldex Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $250 million.

Celldex Therapeutics, Inc. to Report Fiscal Year 2023 Results on Feb 26, 2024

Full year 2023 earnings released: US$2.92 loss per share (vs US$2.40 loss in FY 2022)

Celldex Therapeutics, Inc. has completed a Follow-on Equity Offering.

New minor risk - Shareholder dilution

Celldex Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $200.475 million.

Celldex Therapeutics, Inc. has filed a Follow-on Equity Offering.

Celldex Therapeutics Announces Positive Topline Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria

New major risk - Share price stability

New major risk - Revenue and earnings growth

Third quarter 2023 earnings released: US$0.81 loss per share (vs US$0.57 loss in 3Q 2022)

Celldex Announces Acceptance of Abstract for Barzolvolimab Phase 1B Results in Prurigo Nodularis At 12Th World Congress on Itch 2023

New major risk - Revenue and earnings growth

New major risk - Revenue and earnings growth

Second quarter 2023 earnings released: US$0.65 loss per share (vs US$0.77 loss in 2Q 2022)

Celldex Therapeutics, Inc. Announces Completion of Enrollment in Phase 2 Study of Barzolvolimab in Patients with Chronic Spontaneous Urticaria

Celldex Therapeutics, Inc. Announces First Patient Dosed in Phase 2 Study of Barzolvolimab in Eosinophilic Esophagitis

Now 22% undervalued after recent price drop

Celldex Therapeutics, Inc. Presents Positive Data from Barzolvolimab Chronic Urticaria Program at EAACI 2023

Celldex Therapeutics Announces Upcoming Barzolvolimab Presentations at EAACI 2023

Celldex Therapeutics, Inc. Announces First Patient Dosed in Phase 1 Study of Cdx-585 in Patients with Advanced Malignancies

Celldex Therapeutics Presents Positive Preclinical Data from TSLP/SCF Bispecific Antibody Program CDX-622

First quarter 2023 earnings released: US$0.62 loss per share (vs US$0.49 loss in 1Q 2022)

Full year 2022 earnings released: US$2.40 loss per share (vs US$1.65 loss in FY 2021)

Celldex Therapeutics, Inc. Announces Appointment of Rita Jain, M.D. to Board of Directors

Celldex Therapeutics Presents Positive Data from Barzolvolimab Phase 1B Study in Chronic Inducible Urticaria At Global Urticaria Forum 2022

Second quarter 2022 earnings released: US$0.77 loss per share (vs US$0.34 loss in 2Q 2021)

Celldex Announces First Patient Dosed in Phase 2 Study of Barzolvolimab in Patients with Chronic Inducible Urticaria

Celldex Therapeutics, Inc. Presents Positive Interim Data from Barzolvolimab Phase 1b Study in Chronic Spontaneous Urticaria at EAACI 2022

Celldex Therapeutics, Inc. Announces First Patient Dosed in Phase 2 Study of Barzolvolimab in Patients with Chronic Spontaneous Urticaria

Celldex Therapeutics, Inc. Announces Board Appointments

First quarter 2022 earnings released: US$0.49 loss per share (vs US$0.42 loss in 1Q 2021)

Insufficient new directors

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Celldex Announces First Patient Dosed in Phase 1 Study of CDX-0159 in Prurigo Nodularis

Third quarter 2021 earnings released: US$0.45 loss per share (vs US$0.36 loss in 3Q 2020)

Celldex Therapeutics, Inc. Announces Initiation of CDX-0159 Subcutaneous Formulation Study

Second quarter 2021 earnings released: US$0.34 loss per share (vs US$0.50 loss in 2Q 2020)

Celldex Presents Preliminary Data from Ongoing CDX-527 Phase 1 Dose Escalation Trial

Celldex Therapeutics, Inc. Announces Acceptance of Abstract for CDX-0159 Phase 1b Results in Inducible Urticaria for Late-Breaking Presentation at the European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress 2021